Century Therapeutics (IPSC)
(Delayed Data from NSDQ)
$0.48 USD
-0.03 (-5.88%)
Updated Sep 19, 2025 03:59 PM ET
After-Market: $0.49 +0.01 (2.68%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IPSC 0.48 -0.03(-5.88%)
Will IPSC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IPSC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IPSC
All You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong Buy
Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock
IPSC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates
Other News for IPSC
Fell Below 20 Day Moving Average appears for IPSC after 5.88% move
Is IPSC set to rally? Crossed Above 20 Day Moving Average shows up after gaining 3.07%
IPSC forms 20 Day Moving Average Resistance on September 17
IPSC forms Doji - Bullish? on September 16
Is IPSC positioned for a breakdown? 20 Day Moving Average Resistance shows up after slipping 0.72%